Glargine safety, diabetes and cancer

Expert Opinion on Drug Safety

Volumn 12, Issue 2, 2013, Pages 247-263

  Rendell, Marc ^a   Akturk, Halis Kaan ^a   Tella, Sri Harsha ^a  

^a Creighton Diabetes Center   (United States)

Author keywords

Breast cancer; Colorectal cancer; Diabetes; Endometrial cancer; Hepatocellular cancer; Insulin glargine; Pancreatic cancer; Renal cancer

Indexed keywords

HUMAN INSULIN; INSULIN GLARGINE; METFORMIN; SOMATOMEDIN C RECEPTOR;

ALCOHOL CONSUMPTION; ALCOHOLISM; ALLERGY; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; DIABETES MELLITUS; DIET; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG SAFETY; EMBRYOTOXICITY; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY CANCER; LIVER CELL CARCINOMA; LYMPHOMA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; PREGNANCY; RETINOPATHY; UROGENITAL SYSTEM;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84874161645     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.770469     Document Type: Article

References (150)

1. Bolli G B, Owens DR. Insulin Glargine. Lancet 2000;356(9228):443-5 (Pubitemid 30496809)
2. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-Acting human insulin analog Glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-8
3. Owens D R, Coates P A, Luzio S D, et al. Pharmacokinetics of 125I-labeled insulin Glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23(6):813-19 (Pubitemid 30414199)
4. Heise T, Bott S, Rave K, et al. No evidence for accumulation of insulin Glargine (LANTUS): B multiple injection study in patients with type 1 diabetes. Diabet Med 2002;19(6):490-5 (Pubitemid 34639160)
5. Rosenstock J, Schwartz S L, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin Glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-6
6. Fulcher G R, Gilbert R E, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35(9):536-42 (Pubitemid 41291382)
7. LANTUS- Prescribing Information insulin glargine [rDNA origin] injection. Available from: Http://products.sanofi.us/lantus/lantus.html [Last accessed 25 October 2012
8. Lepercq J, Lin J, Hall G C, et al. Meta-Analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012;2012:649070
9. Radermecker R P, Scheen AJ. Allergy reactions to insulin: Effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007;23(5):348-55 (Pubitemid 47091237)
10. Karges B, Muche R, Riegger I, et al. Injection of acidic or neutral insulin and pain: B single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Clin Ther 2006;28(12):2094-101 (Pubitemid 46215750)
11. McKeage K, Goa KL. Insulin glargine: B review of its therapeutic use as a long-Acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61(11):1599-624 (Pubitemid 32905280)
12. Milazzo G, Sciacca L, Papa V, et al. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 1997;18(1):19-25 (Pubitemid 27107371)
13. Shymko R M, Dumont E, DeMeyts P, Dumont JE. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: B plausible model based on coincidence of hormone and effector binding. Biochem J 1999;339(PT3):675-83 (Pubitemid 29243532)
14. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49(6):999-1005 (Pubitemid 30349423)
15. Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: Bctions via insulin and IGF receptors. Acta Diabetol 2010;47(4):271-8
16. Sciacca L, Cassarino M F, Genua M, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signaling. Diabetologia 2010;53(8):1743-53
17. Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I-like mitogenic and anti-Apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25(1):41-9
18. Slawik M, Schories M, Busse Grawitz A, et al. Treatment with insulin glargine does not suppress serum IGF-1. Diabet Med 2006;23(7):814-17 (Pubitemid 44366083)
19. Smith L E, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5(12):1390-5
20. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82(7):725-30 (Pubitemid 28376897)
21. Henricsson M, Berntorp K, Fernlund P, Sundkvist G. Progression of retinopathy in insulin-Treated type 2 diabetic patients. Diabetes Care 2002;25(2):381-5 (Pubitemid 41079640)
22. Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: B long-Term, randomised, open-label study. Diabetologia 2009;52(9):1778-88
23. Hemkens L G, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: B cohort study. Diabetologia 2009;52(9):1732-44
24. Jonasson J M, Ljung R, Talbäck M, et al. Insulin glargine use and short-Term incidence of malignancies - A populationbased follow-up study in Sweden. Diabetologia 2009;52(9):1745-54
25. Ljung R, Talbäck M, Haglund B, et al. Insulin glargine use and short-Term incidence of malignancies - A three-year population-based observation. Acta Oncol 2011;50(5):685-93
26. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: B study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52(9):1755-65
27. Fagot J P, Blotière P O, Ricordeau P, et al. Does insulin glargine increase the risk of cancer compared with other Basal insulins?: B French nationwide cohort study based on national administrative databases. Diabetes Care 2012;published online Sep 2012; DOI: 10.2337/dc12-0506
28. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: B cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55(3):644-53
29. Currie C J, Poole C D, Gale EAM, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia 2009;52(9):1971-3
30. Origin Trial Investigators. Gerstein HC, Bosch J, Dagenais G R, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-28
31. Inoue M, Iwasaki M, Otani T, et al. Japan Public Health Center-based Prospective Study Group. Diabetes mellitus and the risk of cancer: Results from a large-scale population-based cohort study in Japan. Arch Int Med 2006;166:1871-7 (Pubitemid 44455170)
32. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-7 (Pubitemid 46354334)
33. Jee S H, Ohrr H, Sull J W, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202 (Pubitemid 40095870)
34. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006;49:945-52
35. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: B systematic review and meta-Analysis. Endocr Pract 2011;17(4):616-28
36. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: B systematic review and meta-Analysis of cohort studies. Int J Cancer 2012;130(7):1639-48
37. Davila J A, Morgan R O, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: B population based case control study. Gut 2005;54(4):533-9 (Pubitemid 40403031)
38. El-Serag H B, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: B systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4(3):369-80 (Pubitemid 43343895)
39. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: B meta-Analysis of cohort studies. Eur J Cancer 2011;47(13):1928-37
40. Huxley R, Ansary M, Berrington D, et al. Type-II diabetes and pancreatic cancer: B meta-Analysis of 36 studies. Br J Cancer 2005;92(11):2076-83 (Pubitemid 40897433)
41. Li D, Tang H, Hassan M, et al. Diabetes and risk of pancreatic cancer: B pooled analysis of three large case-control studies. Cancer Causes Control 2011;22(2):189-97
42. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-Analysis. JAMA 1995;273(20):1605-9
43. Ren H B, Yu T, Liu C, Li YQ. Diabetes mellitus and increased risk of biliary tract cancer: Systematic review and meta-Analysis. Cancer Causes Control 2011;22(6):837-47
44. Jing W, Jin G, Zhou X. Diabetes mellitus and increased risk of cholangiocarcinoma: B meta-Analysis. Eur J Cancer Prev 2012;21(1):24-31
45. Magruder J T, Elahi D, Andersen DK. Diabetes and pancreatic cancer: Chicken or egg? Pancreas 2011;40(3):339-51
46. Giouleme O, Diamantidis M, Katsaros M. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011;17(4):444-8
47. Larsson S, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: B meta-Analysis. J Natl Cancer Inst 2005;97(22):1679-87 (Pubitemid 41672234)
48. Yuhara H, Steinmaus C, Cohen E, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011;106(11):1911-21
49. Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer: B systematic review and meta-Analysis of cohort studies. Eur J Epidemiol 2011;26(11):863-76
50. Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: Bn updated systematic review and meta-Analysis. Dig Dis Sci 2012;57(6):1576-85
51. Huang W, Ren H, Ben Q, et al. Risk of esophageal cancer in diabetes mellitus: B meta-Analysis of observational studies. Cancer Causes Control 2012;23(2):263-72
52. Larsson S, Wolk A. Diabetes mellitus and incidence of kidney cancer: B meta-Analysis of cohort studies. Diabetologia 2011;54(5):1013-18
53. Larsson S C, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: B meta-Analysis. Diabetologia 2006;49(12):2819-23 (Pubitemid 44730282)
54. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: B meta-Analysis of the literature. Asian Pac J Cancer Prev 2011;12(4):1061-5
55. Larsson S C, Mantzoros C S, Wolk A. Diabetes mellitus and risk of breast cancer: B meta-Analysis. Int J Cancer 2007;121(4):856-62 (Pubitemid 47106217)
56. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: B meta-Analysis. Diabetologia 2007;50(7):1365-74 (Pubitemid 46879010)
57. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: B meta-Analysis. Diabetologia 2004;47:1071-8 (Pubitemid 38918167)
58. Kasper J S, Giovannucci E. A meta-Analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2056-62 (Pubitemid 44877026)
59. Rendell M, Kimmel D, Bamisedun O, et al. The health care status of the diabetic population as reflected by physician claims to a major insurer. Arch Intern Med 1993;153(11):1360-6 (Pubitemid 23169929)
60. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50 (Pubitemid 32378388)
61. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368(9548):1673-9 (Pubitemid 46048554)
62. WCRF/AICR Ed 2007 World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: B global perspective. AICR, Washington DC; 2007
63. Reis J P, Loria C M, Sorlie P D, et al. Lifestyle factors and risk for new-onset diabetes: B population-based cohort study. Ann Intern Med 2011;155(5):292-9
64. Jiao L, Mitrou P N, Reedy J, et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med 2009;169(8):764-70
65. Mitrou P N, Kipnis V, Thie'baut A C, et al. Schatzkin mediterranean dietary pattern and prediction of all-cause mortality in a US population: Results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007;167(22):2461-8 (Pubitemid 350254905)
66. Aune D, Chan D S, Greenwood DC, et al. Dietary fiber and breast cancer risk: B systematic review and meta-Analysis of prospective studies. Ann Oncol 2012;23(6):1394-402
67. Magalhäes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: Systematic review and meta-Analysis. Eur J Cancer Prev 2012;21(1):15-23
68. Flood A, Rastogi T, Wirfält E, et al. Dietary patterns as identified by factor analysis and colorectal cancer among middle-Aged Americans. Am J Clin Nutr 2008;88(1):176-84 (Pubitemid 351988698)
69. Ruder E H, Thie'baut A C, Thompson FE, et al. Adolescent and mid-life diet: Risk of colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr 2011;94(6):1607-19
70. Gao C, Yao SK. Diabetes mellitus: B "true" independent risk factor for hepatocellular carcinomä Hepatobiliary Pancreat Dis Int 2009;8(5):465-73
71. Parry C D, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: Epidemiology and policy implications. Addiction 2011;106(10):1718-24
72. Lowenfels A B, Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 2002;16(1):1-16 (Pubitemid 34578623)
73. Go V L, Gukovskaya A, Pandol SJ. Alcohol and pancreatic cancer. Alcohol 2005;35(3):205-11 (Pubitemid 41079924)
74. Lew J Q, Chow W H, Hollenbeck AR, et al. Alcohol consumption and risk of renal cell cancer: The NIH-AARP diet and health study. Br J Cancer 2011;104(3):537-41
75. Johnson J A, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: B meta-Analysis of major trials. Diabetologia 2011;54(1):25-31
76. Inoue M, Tsugane S. Insulin resistance and cancer: Epidemiological evidence. Endocr Relat Cancer 2012;19(5):F1-8
77. Gallagher E J, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diabet Rep 2010;10(2):93-100
78. Schiel R, Beltschikow W, Steiner T, Stein G. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006;28(3):169-75 (Pubitemid 43938540)
79. Müssig K, Staiger H, Kantartzis K, et al. Diabetes, insulin, insulin analogues, and cancer. Dtsch Med Wochenschr 2010;135(18):924-9
80. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005;87(1):99-109 (Pubitemid 40298772)
81. Sun X J, Rothenberg P, Kahn C R, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991;352(6330):73-7 (Pubitemid 21896701)
82. Reiss K, Del Valle L, Lassak A, Trojanek J. Nuclear IRS-1 and cancer. J Cell Physiol 2012;227(8):2992-3000
83. Shaw LM. The insulin receptor substrate (IRS) proteins: Bt the intersection of metabolism and cancer. Cell Cycle 2011;10(11):1750-6
84. Pepe M G, Ginzton N H, Lee P D, et al. Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells. J Cell Physiol 1987;133(2):219-27 (Pubitemid 18007520)
85. Polychronakos C, Janthly U, Lehoux JG, Koutsilieris M. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: Characterization of the receptors involved. Prostate 1991;19(4):313-21
86. Neely E K, Morhenn V B, Hintz RL, et al. Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma. J Invest Dermatol 1991;96(1):104-10
87. Oku K, Tanaka A, Yamanishi H, et al. Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium. Anticancer Res 1991;11:1591-5
88. Singh P, Dai B, Yallampalli U, et al. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: Role of IGF-II. Endocrinology 1996;137:1764-74
89. Frostad S, Bruserud O. In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. Eur J Haematol 1999;62:191-8 (Pubitemid 29111485)
90. Khandwala H M, McCutcheon IE, Flyvberg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44 (Pubitemid 32275588)
91. Le Roith D. Seminars in medicine on the Beth Israel Deaconess Medical Center: Insulin-like growth factors. N Engl J Med 1997;336:633-40
92. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92(18):1472-89
93. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20
94. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9
95. Major J M, Laughlin GA, Kritz-Silverstein D, et al. Insulin-like growth factor-1 and cancer mortality in older men. J Clin Endocrinol Metab 2010;95:1054-9
96. Gallagher E J, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011;152(7):2546-51
97. Stammberger I, Bube A, Durchfeld-Meyer B, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21(3):171-9 (Pubitemid 34803492)
98. Kuerzel G U, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19(1):34-40 (Pubitemid 36378318)
99. Pierre-Eugene C, Pagesy P, Nguyen TT, et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLoS One 2012;7(7):e41992
100. Ciaraldi T P, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: Potential implications for metabolic and mitogenic activities. Horm Metab Res 2011;43(1):1-10
101. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: B meta-Analysis. Diabetologia 2009;52(12):2507-12
102. Gatto N M, Bracken M B, Lem J, et al. Comparative lung cancer mortality with inhaled insulin or comparator: FUSE Final Results. Presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 24 Augest 2012, Barcelona, Spain
103. Davidson M B, Peters AL. An overview of metformin in the treatment of type-2 diabetes mellitus. Am J Med 1997;102(1):99-110 (Pubitemid 27089992)
104. Zimmet P, Collier G. Clinical efficacy of metformin against insulin resistance parameters: Sinking the iceberg. Drugs 1999;58(SUPPL1):21-8; discussion 75-82
105. Mehnert H.Metformin, the rebirth of a biguanide: Mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001;109(SUPPL2):S259-64 (Pubitemid 32577586)
106. Libby G, LDonnelly L A, Donnan PT, et al. New users of metformin are at low risk of incident cancer: B cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-5
107. Ruiter R, Loes E, Visser L E, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 2012;35(1):119-24
108. Lee M S, Hsu C C, Wahlqvist M L, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: B representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20-0
109. Landman G W, Kleefstra N, van Hateren K J, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33(2):322-6
110. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: B systematic review and meta-Analysis. PLoS One 2012;7(3):e33411
111. Nananda F, Ochs L, Springmann V, et al. Metformin and breast cancer risk: B meta-Analysis and critical literature review. Breast Cancer Res Treat 2012;135(3):639-46
112. Currie C, Poole C, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012;35(2):299-304
113. Garrett G M, Hassabo HM, Bhadkamkar N A, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer SO. Br J Cancer 2012;106(8):1374-8
114. Lee J, Kim T, Jeon S M, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012;131(3):752-9
115. Romero I L, McCormick A, McEwen K A, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012;119(1):61-7
116. Bowker S L, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Bssessing effects of time-varying exposure. Diabetologia 2010;53(8):1631-7
117. Song C, Lee W, Dings R, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012;2:362-2
118. Walter H, Saumet G, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;246-50
119. Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.Mol Cancer Ther 2012;11(3):1-12
120. Jung J W, Park S B, Lee S, et al. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 Expression. PLoS One 2011;6(11):e28068
121. Schauer I E, Snell-Bergeon J K, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes. Diabetes 2011;60(1):306-14
122. Zendehdel K, Nyre'n O, Ostenson CG, et al. Cancer incidence in patients with type 1 diabetes mellitus: B population-based cohort study in Sweden. J Natl Cancer Inst 2003;95(23):1797-800 (Pubitemid 38008903)
123. Shu X, Ji J, Li X, et al. Cancer risk among patients hospitalized for type 1 diabetes mellitus: B population-based cohort study in Sweden. Diabet Med 2010;27(7):791-7
124. Calle E E, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348(17):1625-38 (Pubitemid 36459468)
125. Caldwell S H, Crespo D M, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(5 SUPPL1):S97-103 (Pubitemid 39423375)
126. Starley B Q, Calcagno C J, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: B weighty connection. Hepatology 2010;51(5):1820-32
127. Moghaddam A A, Woodward M, Huxley R. Obesity and risk of colorectal cancer: B meta-Analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16(12):2533-47 (Pubitemid 351196307)
128. Hardy O T, Czech M P, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes 2012;19(2):81-7
129. Gupta D, Krueger C B, Lastra G. Overnutrition, obesity and insulin resistance in the development of beta-cell dysfunction. Curr Diabetes Rev 2012;8(2):76-83
130. Morimoto L M, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 2002;13(8):741-51 (Pubitemid 35204050)
131. Eliassen A H, Colditz G A, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296(2):193-201 (Pubitemid 44050373)
132. Chen J. Multiple signal pathways in obesity-Associated cancer. Obes Rev 2011;12(12):1063-70
133. Harvey A E, Lashinger L M, Hursting SD. The growing challenge of obesity and cancer: Bn inflammatory issue. Ann NY Acad Sci 2011;1229:45-52
134. Dossus L, Rinaldi S, Becker S, et al. Obesity, inflammatory markers, and endometrial cancer risk: B prospective case-control study. Endocr Relat Cancer 2010;17(4):1007-19
135. Drew JE. Molecular mechanisms linking adipokines to obesity-related colon cancer: Focus on leptin. Proc Nutr Soc 2012;71(1):175-80
136. Ho G Y, Wang T, Gunter M J, et al. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012;72(12):3029-37
137. Emerging Risk Factors Collaboration. Sarwar N, Gao P, Seshasai S R, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: B collaborative meta-Analysis of 102 prospective studies. Lancet 2010;375(9733):2215-22
138. Zhou X H, Qiao Q, Zethelius B, et al. DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia 2010;53(9):1867-76
139. Hoyert D, Jiaquan X. Deaths: Preliminary data for 2011. Natl Vital Stat Rep 2012;61:6
140. Garg S K, Gottlieb P A, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49-56 (Pubitemid 39201371)
141. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin patients with type 1 diabetes given rapid-Acting insulin analog at mealtime; a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003;26:1490-96 (Pubitemid 36929184)
142. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin Lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71
143. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-42 (Pubitemid 30616802)
144. Chase H P, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and Neutral Protamine Hagedorn insulin. J Pediatr 2003;143:737-40 (Pubitemid 37510641)
145. Murphy N P, Keane S M, Ong K K, et al. Randomized cross-over trial of insulin glargine plus Lispro or NPH inulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804 (Pubitemid 36929346)
146. Yki J H, Dressler A, Ziemen M; HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 study Group. Diabetes Care 2000;23:1130-6 (Pubitemid 30616801)
147. Rosenstock J, Shwartz S L, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6 (Pubitemid 32888839)
148. Mitri J, Castillo J, Pittas A. Diabetes and risk of non-Hodgkin's lymphoma: B meta-Analysis of observational studies. Diabetes Care 2008;31(12):2391-7
149. Chao C, Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: B systematic review and meta-Analysis. Am J Epidemiol 2008;168(5):471-80
150. Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf 2013;12(2):195-207